Mitotane (C14H10Cl4 - CAS# 53-19-0) is a cancer (antineoplastic) medication. Mitotane interferes with the growth of cancer cells and slows their growth and spread in the body. Mitotane is used to treat cancer of the adrenal gland (adrenal Mitotane may also be used for purposes other than those listed in this medication guide.
Action/Kinetics: Directly suppresses activity of adrenal cortex and changes the peripheral metabolism of corticosteroids, resulting in a decrease in 17-hydroxycorticosteroids. About 40% absorbed from GI tract; detectable in serum for 6-9 weeks after administration. Mostly stored in adipose tissue. t1/2: After therapy terminated, 18-159 days. Unchanged drug is excreted in the feces while metabolites are excreted in the urine. Steroid replacement therapy may have to be instituted (i.e., increased) to correct adrenal insufficiency. Therapy is continued as long as drug seems effective. Beneficial results may not become apparent until after 3 months of therapy.
Mitotane appears to suppress activity (steroid production) in the adrenal cortex. For reasons that are unknown, the drug's reduction of steroid production somehow has a destructive effect on cancer cells in the adrenal cortices, and so slows the progression of cancer in that portion of the adrenal gland.